AMYRIS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.001 USD | -33.33% |
|
-33.33% | -60.00% |
| 03-13 | North American Morning Briefing : Stock Futures -2- | DJ |
| 01-22 | Third Amended Joint Reorganization Plan Filed by Amyris, Inc. | CI |
| Sales 2021 | 342M 27.37B | Sales 2022 | 270M 21.61B | Capitalization | 556M 44.53B |
|---|---|---|---|---|---|
| Net income 2021 | -271M -21.7B | Net income 2022 | -529M -42.36B | EV / Sales 2021 | 4.77 x |
| Net cash position 2021 | 38.36M 3.07B | Net Debt 2022 | 917M 73.43B | EV / Sales 2022 | 5.46 x |
| P/E ratio 2021 |
-5.55
x | P/E ratio 2022 |
-0.9
x | Employees | 1,598 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 94.16% |
More Fundamentals
* Assessed data
More news
Latest transcript on Amyris, Inc.
More recommendations
More press releases
More news
| 1 day | -33.33% | ||
| 1 week | -33.33% | ||
| Current month | -83.33% | ||
| 1 month | -50.00% | ||
| 3 months | -41.18% | ||
| 6 months | -75.00% | ||
| Current year | -60.00% |
1 week
0.00
0.01
1 month
0.000.01
Current year
0.000.02
1 year
0.001.32
3 years
0.0017.42
5 years
0.0023.42
10 years
0.0067.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 15/03/20 | |
Sunil Chandran
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/05 |
Sola Biu
SAM | Sales & Marketing | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Steven Mills
BRD | Director/Board Member | 68 | 31/07/18 |
M. Reiss
BRD | Director/Board Member | 77 | 08/08/23 |
John Doerr
BRD | Director/Board Member | 72 | 30/04/06 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.001 | -33.33% | 28,002 |
| 25/04/24 | 0.0015 | +50.00% | 18,196 |
| 24/04/24 | 0.001 | -64.29% | 94,887 |
| 22/04/24 | 0.0028 | +86.67% | 143,848 |
| 19/04/24 | 0.0015 | 0.00% | 35,060 |
Delayed Quote OTC Markets, April 26, 2024 at 08:40 pm
More quotes
Amyris, Inc. is a synthetic biotechnology company. The component of the Company is derived from marketing and selling Clean Beauty, Personal Care, and Health & Wellness consumer products through its direct-to-consumer e-commerce platforms and a growing network of retail partners. The Companyâs sustainable ingredients are sold in bulk to industrial leaders who serve Flavor & Fragrance (F&F), Nutrition, Food & Beverage, and Clean Beauty & Personal Care end markets. The ingredients and consumer products it produces by its Lab-to-Market technology platform. The Company leverages machine learning, robotics, and artificial intelligence, which enables its technology platform to rapidly bring new market at commercial scale. The Lab-to-Market technology platform utilizes optimized and automated molecular biology, analytical, and process development tools combined with machine learning algorithms and statistical models to transform the way microbes metabolize sugars.
Sector
Specialty Chemicals
Calendar
06/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -60.00% | 372K | |
| +11.47% | 63.22B | |
| -3.47% | 46.34B | |
| +13.72% | 39.97B | |
| +17.83% | 25.46B | |
| +7.27% | 18.68B | |
| -0.57% | 17.24B | |
| -21.73% | 15.81B | |
| +0.22% | 14.9B | |
| -19.10% | 13.74B |
- Stock Market
- Equities
- AMRSQ Stock
